Intelligence · Patents
Patents expiring in 2040
Annual patent cliff calendar for 2040 — US pharmaceutical patents by expiration date.
- Patents
- 1,866
Quick answer
1,866 indexed pharmaceutical patents have expiration dates in 2040. Browse by soonest expiry with links to assignee companies and related drugs.
-
US 10676498
Processes for the preparation of sofosbuvir and intermediates thereof
granted -
US 10676527
Methods and compositions for modulation of blood-neural barrier
granted -
US 10676475
Compounds for improving mRNA splicing
granted -
US 10676452
Compound for the prophylaxis or treatment of organ damage
granted -
US 10675482
Device and method for use of photodynamic therapy
granted -
US 10675360
Targeted therapeutics
granted -
US 10676442
Salt derivative of tetrahydroisoquinoline and crystalline thereof and preparation method therefore and application thereof
granted -
US 10675488
Acne removing skin care product and preparation method thereof
granted -
US 10676461
Heterocyclic compound
granted -
US 10675348
Antibodies that bind human C6 and uses thereof
granted -
US 10675324
Compositions and methods for modulating AT2R activity
granted -
US 10676473
Solid state forms of fused heteroaromatic pyrrolidinones
granted -
US 10675356
Peptide oligonucleotide conjugates
granted -
US 10675325
Stable formulations of linaclotide
granted -
US 10675273
Benzothiazole amphiphiles
granted -
US 10675307
Compositions comprising perivascular stem cells and nell-1 protein
granted -
US 10675303
Extracellular matrix compositions for the treatment of cancer
granted -
US 10676469
Kappa opioid receptor antagonists and products and methods related thereto
granted -
US 10675302
Methods and compositions for targeted cleavage and recombination
granted -
US 10675267
Methods for detection and eradication of myeloid leukemia stem cells
granted -
US 10675283
Compositions and methods for white to beige adipogenesis
granted -
US 10675271
Clonidine and/or clonidine derivatives for use in the prevention and/or treatment of adverse side effects of chemotherapy
granted -
US 10675246
Orally administrable compositions comprising calcium
granted -
US 10674901
Minimally-invasive measurement of esophageal inflammation
granted -
US 10675245
Sustained release formulation of a non-steroidal anti-inflammatory drug
granted -
US 10677801
Diagnosis and treatment of breast cancer
granted -
US 10675308
Chinese medicine extract and preparation method and application thereof
granted -
AU 2018379646
Dopamine-B-hydroxylase inhibitors
granted -
US 10682350
2,4-pyrimidinediamine compounds and their uses
granted -
US 10683270
Cannabinoid receptor mediating compounds
granted -
US 10683503
Antisense oligomers for treatment of conditions and diseases
granted -
US 10683366
Methods and compositions for treatment of atherosclerosis
granted -
US 10683504
Serpina1 iRNA compositions and methods of use thereof
granted -
US 10683530
Detection of oligosaccharides
granted -
US 10683500
UNA oligomers having reduced off-target effects in gene silencing
granted -
US 10683501
Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases
granted -
US 10683499
Compositions and methods for modulating TTR expression
granted -
US 10683283
Substituted ureas and methods of making and using same
granted -
US 10683354
Antibody-drug conjugates comprising anti-prolactin receptor (PRLR) antibodies and methods of use thereof to kill PRLR-expressing cells
granted -
US 10683316
Synthetic catalase/superoxide dismutase mimetics and methods for treating viral infections
granted -
US 10683330
Campylobacter immunogenic compositions and uses thereof
granted -
US 10682368
Methods of treating feline coronavirus infections
granted -
US 10683277
Triazole derivatives as P2Y14 receptor antagonists
granted -
US 10682425
Engineered B lymphocytes and compositions having micro-RNA and methods for making and using them
granted -
US 10682416
Epicardial-derived paracrine factors for repairing cardiac tissue
granted -
US 10682393
Glial cell line derived neurotrophic factor, obesity, and obesity-related diseases and conditions
granted -
US 10682388
Targeting of PELP1 in cancer therapy
granted -
US 10682339
Pharmaceutical compositions directly targeting FKBP52 for the treatment of prostate cancer and methods of using same
granted
Frequently asked questions
How many pharma patents expire in 2040?
1,866 published patents in our USPTO index have expiration dates falling in calendar year 2040.